Nmc Biopharm Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
as on 01-01-2025
- Paid Up Capital ₹ 14.00 Cr
as on 01-01-2025
- Company Age 22 Year, 11 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 21.70 Cr
as on 01-01-2025
- Revenue %
(FY 2021)
- Profit 27.19%
(FY 2021)
- Ebitda 78.20%
(FY 2021)
- Net Worth -48.02%
(FY 2021)
- Total Assets -3.47%
(FY 2021)
About Nmc Biopharm
The Corporate was formerly known as Nmc Overseas Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 14.00 Cr.
The company currently has active open charges totaling ₹21.70 Cr.
Naveen Chaudhri, Amita Chaudhri, and Ananjan Chaudhri serve as directors at the Company.
- CIN/LLPIN
U24231DL2002PLC114170
- Company No.
114170
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
11 Feb 2002
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nmc Biopharm?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naveen Chaudhri  | Managing Director | 11-Feb-2002 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ananjan Chaudhri | Additional Director | 02-Apr-2018 | Current |
| Amita Chaudhri | Additional Director | 14-Aug-2017 | Current |
Financial Performance of Nmc Biopharm.
Nmc Biopharm Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 27.19% increase in profit. The company's net worth observed a substantial decline by a decrease of 48.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nmc Biopharm?
In 2021, Nmc Biopharm had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rancan Impex Private LimitedActive 35 years 6 monthsNaveen Chaudhri and Amita Chaudhri are mutual person
- Nmc-Sky Diagnostics Private LimitedActive 30 years 4 months
Naveen Chaudhri and Amita Chaudhri are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Delhi Safe Depostis Company Limited Creation Date: 24 Dec 2014 | ₹7.00 M | Open |
Dhanlaxmi Bank Limited Creation Date: 23 Apr 2012 | ₹20.00 Cr | Open |
Vijaya Bank Creation Date: 27 Aug 2002 | ₹5.00 M | Open |
How Many Employees Work at Nmc Biopharm?
Unlock and access historical data on people associated with Nmc Biopharm, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nmc Biopharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nmc Biopharm's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
